cytokin
storm
driver
patholog
mortal
myriad
viral
infect
affect
human
popul
patient
strength
cytokin
storm
associ
increas
risk
acut
respiratori
distress
syndrom
myocardi
damag
death
howev
therapeut
valu
attenu
cytokin
storm
remain
defin
report
result
obtain
use
novel
mous
model
lethal
steril
antivir
immun
respons
use
mous
model
syndrom
ds
segment
duplic
genom
region
encod
four
six
interferon
receptor
gene
ifnr
demonstr
anim
overexpress
ifnr
hypersensit
ifn
stimul
challeng
viral
mimet
activ
tolllik
receptor
signal
ifn
antivir
respons
anim
overproduc
key
cytokin
show
exacerb
liver
patholog
rapidli
lose
weight
die
importantli
lethal
immun
hypersensit
accompani
cytokin
storm
liver
hyperinflamm
block
treatment
inhibitor
therefor
result
point
inhibit
potenti
strategi
attenu
cytokin
storm
consequ
organ
failur
overdr
immun
respons
addit
result
indic
peopl
ds
carri
extra
copi
ifnr
gene
cluster
encod
chromosom
consid
high
risk
pandem
progress
toward
ard
altogeth
find
support
rational
combin
antivir
treatment
target
immunosuppress
therapeut
approach
accordingli
sever
clinic
trial
current
test
safeti
efficaci
inhibitor
signal
jakstat
signal
furthermor
hydroxychloroquin
molecul
shown
attenu
tolllik
receptor
signal
cytokin
product
approv
treatment
rheumatoid
arthriti
system
lupu
erythematosu
also
test
mani
clinic
trial
within
context
report
relev
result
obtain
studi
hyperact
immun
respons
mous
model
syndrom
ds
recent
discov
trisomi
genet
caus
ds
caus
consist
activ
ifn
transcript
respons
multipl
cell
type
explain
fact
four
six
ifn
receptor
encod
chromosom
addit
investig
proteom
metabolom
immun
cell
lineag
peopl
ds
demonstr
caus
chang
circul
proteom
indic
chronic
autoinflamm
clear
dysregul
ifninduc
cytokin
activ
ifninduc
kynurenin
pathway
lead
elev
product
neurotox
tryptophan
catabolit
widespread
hypersensit
ifn
stimul
encod
gene
includ
four
ifnr
found
mice
overexpress
ifnr
immun
cell
type
test
display
hypersensit
type
type
ii
ifn
stimul
overproduc
key
cytokin
display
increas
liver
inflamm
remark
mice
display
lethal
immun
respons
upon
challeng
viral
mimet
molecul
agonist
polyi
c
p
c
agonist
imiquimod
phenotyp
observ
wild
type
wt
litterm
mous
strain
carri
triplic
genom
region
synten
chromosom
strikingli
lethal
immun
phenotyp
associ
cytokin
storm
block
treatment
small
molecul
inhibitor
kinas
also
decreas
liver
patholog
overal
result
potenti
farreach
signific
treatment
justifi
deeper
studi
jak
inhibitor
therapeut
strategi
attenu
cytokin
storm
downstream
organ
failur
condit
also
indic
individu
ds
consid
highrisk
popul
pandem
order
model
impact
chronic
innat
immun
respons
mice
employ
mous
strain
harbor
triplic
region
synten
human
chromosom
includ
four
ifnr
figur
defin
relationship
gene
copi
number
ifnr
protein
express
evalu
surfac
express
peripher
immun
cell
mice
flow
cytometri
dp
dp
yey
mice
hereaft
refer
three
copi
gene
synten
chromosom
disom
ifnr
includ
control
figur
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
express
surfac
white
blood
cell
significantli
higher
mice
anim
rel
wt
litterm
figur
differ
immun
cell
type
analyz
flow
cytometri
express
significantli
higher
cell
type
test
figur
result
consist
previou
report
mrna
overexpress
ifnr
gene
cluster
variou
tissu
mice
test
whether
upregul
ifnr
confer
stronger
respons
ifn
ligand
stimul
wt
blood
sampl
ifna
evalu
downstream
phosphoryl
flow
cytometri
cell
respond
strongli
ifna
defin
significantli
higher
level
rel
wt
cell
immun
lineag
examin
figur
widespread
heighten
respons
ifna
observ
cell
howev
cell
subset
strain
exhibit
robust
figur
although
mice
two
copi
ifnr
gene
result
suggest
aspect
triplic
region
chromosom
synten
human
chromosom
lead
differenti
regul
type
ifn
signal
cell
given
one
type
ii
ifn
receptor
subunit
also
encod
murin
chromosom
triplic
mice
next
investig
respons
ifng
stimul
inde
cell
respond
strongli
ifng
stimul
cell
type
examin
figur
overal
result
suggest
elev
express
ifnr
mous
strain
confer
increas
sensit
type
type
ii
ifn
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
sinc
cell
mount
enhanc
respons
ifn
ligand
next
investig
respons
mice
innat
immun
stimuli
known
trigger
ifn
respons
chronic
system
induct
ifn
signal
elicit
repeat
administr
agonist
polyinosin
polycytidyl
acid
p
c
known
produc
acut
spike
type
ifn
product
day
follow
low
persist
express
type
ifn
ligand
robust
cytokin
respons
chronic
phase
day
wt
mice
given
intraperiton
inject
mgkg
p
c
equival
volum
vehicl
sham
everi
day
day
experi
complet
day
remark
mice
profoundli
sensit
treatment
larg
toler
wt
mice
figur
bodi
weight
measur
cours
experi
reveal
rapid
weight
loss
mice
upon
treatment
figur
eventu
one
twelv
mice
remov
studi
excess
weight
loss
contrast
wt
anim
lose
much
weight
three
nine
surviv
end
experi
figur
b
mice
also
toler
chronic
immun
stimul
p
c
figur
f
although
p
c
treatment
caus
weight
loss
mice
percentag
lost
compar
wt
level
p
c
induc
weight
loss
clearli
dosedepend
mice
receiv
half
lethal
dose
mgkg
display
minor
weight
loss
observ
differ
wt
mice
figur
order
determin
whether
hypersensit
restrict
agonist
broadli
observ
across
activ
pattern
recognit
receptor
treat
mice
agonist
imiquimod
topic
administr
imiquimod
caus
ifn
product
acut
skin
inflamm
system
inflamm
dehydr
commonli
employ
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
model
psoriasi
imiquimod
treatment
caus
signific
weight
loss
mice
despit
daili
administr
support
fluid
led
rapid
termin
studi
observ
human
endpoint
figur
h
contrast
wt
anim
receiv
ident
treatment
maintain
weight
figur
h
altogeth
result
indic
hypersensit
ifn
stimul
observ
cellular
level
mice
associ
increas
sensit
lethal
ifninduc
viral
mimet
agent
organism
level
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
logrank
test
statist
signific
weight
loss
calcul
use
student
ttest
p
p
p
p
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
next
compar
immun
respons
mice
rel
wild
type
litterm
acut
chronic
respons
p
c
first
measur
level
circul
ifna
hour
first
inject
p
c
sham
ifna
level
induc
p
c
stronger
respons
mice
figur
elev
ifn
ligand
product
mice
consist
predict
fastforward
loop
driven
increas
ifnr
express
ds
measur
mrna
express
sever
ifnstimul
gene
isg
spleen
wt
mice
hour
singl
inject
p
c
sham
experi
reveal
strong
induct
isg
express
upon
p
c
treatment
sever
isg
significantli
elev
mice
wt
anim
figur
next
measur
level
sever
cytokin
chemokin
bloodstream
hour
singl
p
c
inject
expectedli
p
c
treat
anim
show
increas
level
mani
proinflammatori
factor
regardless
genotyp
figur
figur
acut
phase
significantli
elev
inflammatori
marker
rant
kcgro
figur
averag
mice
show
signific
differ
express
cytokin
rel
wt
litterm
measur
circul
cytokin
chemokin
chronic
respons
compar
serum
level
mice
taken
time
harvest
due
reach
human
endpoint
weight
loss
level
wt
litterm
surviv
end
experi
later
stage
chronic
inflamm
sever
inflammatori
marker
significantli
elev
anim
wt
litterm
figur
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
altogeth
result
indic
activ
tlr
signal
lead
strong
induct
key
cytokin
chemokin
experiment
paradigm
sever
inflammatori
marker
elev
mice
although
singl
cytokin
chemokin
stand
sole
driver
phenotyp
mice
mild
overproduct
sever
cytokin
could
potenti
contribut
exacerb
immun
sensit
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
versu
mice
cytokin
analysi
peripher
blood
anim
chronic
treat
p
c
sham
indic
sampl
anim
collect
either
human
endpoint
weight
loss
end
experi
day
whichev
occur
first
data
present
mean
sem
statist
signific
calcul
use
student
ttest
p
p
p
p
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
next
investig
marker
liver
inflamm
injuri
serum
level
enzym
alanin
transaminas
alt
aspart
transaminas
ast
two
commonli
use
marker
hepatocyt
injuri
significantli
elev
upon
p
c
treatment
mice
reach
concentr
nearli
order
magnitud
higher
observ
wt
litterm
figur
prompt
result
investig
liver
patholog
liver
tissu
section
stain
hematoxylin
eosin
h
e
evalu
train
histologist
blind
treatment
group
genotyp
score
liver
patholog
done
procedur
adapt
mice
use
valid
histolog
score
system
includ
paramet
cell
injuri
inflamm
reactiv
chang
lead
overal
liver
patholog
score
analysi
reveal
mice
increas
liver
patholog
even
p
c
treatment
demonstr
significantli
higher
level
cell
injuri
inflamm
reactiv
chang
rel
wt
litterm
figur
c
basal
level
liver
patholog
observ
mice
figur
e
importantli
upon
treatment
p
c
liver
wt
anim
develop
patholog
score
compar
greater
observ
baselin
mice
includ
sign
strong
recruit
andor
expans
inflammatori
cell
p
c
administ
mice
metric
liver
patholog
increas
lead
significantli
higher
overal
patholog
score
rel
sham
treatment
wt
upon
p
c
treatment
figur
liver
mice
receiv
p
c
also
experienc
increas
liver
patholog
chang
differ
wt
mice
figur
e
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
overal
result
indic
mice
display
increas
liver
inflamm
patholog
baselin
upon
immun
activ
could
potenti
contribut
heighten
sensit
ifninduc
agent
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
three
type
ifn
signal
employ
kinas
signal
transduct
combin
either
figur
therefor
sought
determin
whether
inhibit
specif
would
block
lethal
patholog
caus
p
c
treatment
mice
end
use
inhibitor
anim
receiv
dose
mgkg
equival
volum
methylcellulos
use
vehicl
twice
daili
via
oral
gavag
begin
hour
prior
first
p
c
inject
everi
day
cours
experi
remark
mice
receiv
inhibitor
surviv
p
c
treatment
anim
receiv
vehicl
p
c
experienc
weight
loss
euthan
figur
analyz
impact
inhibit
cytokin
product
compar
mice
treat
p
c
without
cotreat
inhibitor
importantli
cytokin
product
strongli
abrog
inhibit
figur
figur
lastli
evalu
impact
inhibit
marker
liver
inflamm
injuri
inde
inhibitor
led
reduct
circul
level
alt
ast
well
decreas
overal
liver
patholog
score
figur
altogeth
result
indic
block
catalyt
activ
kinas
prevent
lethal
associ
rampant
innat
immun
respons
mous
model
efficaci
treatment
like
reli
combin
interrel
effect
reduc
cytokin
product
improv
liver
function
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
mgkg
everi
hour
day
b
indic
cytokin
measur
blood
sampl
obtain
figur
chronic
respons
p
c
data
figur
tnfa
figur
compar
valu
parallel
experiment
cohort
mice
cotreat
jaki
c
liver
enzym
liver
patholog
assess
exactli
figur
data
present
mean
sem
statist
signific
kaplanmei
analysi
calcul
use
mantelcox
logrank
test
student
ttest
result
p
p
p
p
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
inhibit
block
cytokin
storm
mice
indic
cytokin
measur
blood
sampl
obtain
figur
chronic
respons
p
c
data
figur
figur
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
pandem
rapidli
progress
worldwid
dire
need
identifi
new
prophylact
therapeut
strategi
base
recent
data
analys
inflammatori
marker
prior
knowledg
inflammatori
respons
lethal
viral
lung
infect
target
immunesuppress
appreci
potenti
strategi
prevent
ard
fulmin
myocard
organ
failur
mortal
advanc
stage
condit
accordingli
clinic
trial
divers
immunesuppress
start
around
world
includ
inhibitor
jakstat
signal
demonstr
key
role
kinas
drive
cytokin
storm
accompani
mortal
mous
model
lethal
antivir
immun
respons
one
sever
jak
kinas
requir
mediat
inflammatori
signal
downstream
larg
number
cytokin
includ
three
type
ifn
signal
show
elicit
innat
antivir
immun
respons
tlr
agonist
lethal
sensit
mous
model
carri
triplic
four
six
ifn
receptor
within
day
mice
rapidli
lose
weight
die
unattend
concurr
induct
mani
promin
cytokin
link
sever
patholog
furthermor
mice
display
exacerb
liver
inflamm
patholog
togeth
stronger
product
cytokin
may
converg
patholog
cascad
lead
wast
death
importantli
phenotyp
block
inhibit
base
result
propos
jak
inhibitor
valid
therapeut
approach
attenu
cytokin
storm
four
jak
inhibitor
current
fdaapprov
treatment
divers
medic
condit
jakafiruxolitinib
inhibitor
approv
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
myelofibrosi
polycythemia
vera
graftversushostdiseas
xeljanztofacitinib
inhibitor
approv
rheumatoid
arthriti
psoriat
arthriti
ulcer
coliti
olumiantbaricitinib
inhibitor
approv
rheumatoid
arthriti
rinvoqupadacitinib
inhibitor
also
approv
rheumatoid
arthriti
mani
inhibitor
current
develop
test
clinic
trial
divers
inflammatori
autoimmun
condit
includ
molecul
use
studi
hypothes
jak
inhibitor
could
superior
agent
term
attenu
cytokin
storm
caus
rel
exist
agent
consist
inject
monoclon
antibodi
inhibit
interact
receptor
contrast
jak
inhibitor
avail
drug
administ
oral
well
character
pharmacodynam
pharmacokinet
may
provid
appropri
strategi
transient
tone
cytokin
storm
prevent
ard
fulmin
myocard
furthermor
inhibitor
block
signal
also
inflammatori
pathway
involv
cytokin
storm
depend
degre
inhibit
variou
jak
kinas
predict
avail
jak
inhibitor
block
variou
aspect
cytokin
storm
potenti
vari
degre
therapeut
benefit
regard
relev
therapeut
strategi
condit
associ
cytokin
storm
studi
sever
limit
first
mous
model
fulli
reproduc
human
condit
associ
cytokin
storm
although
pandem
studi
mice
origin
driven
interest
studi
immun
dysregul
ifn
hyperact
ds
note
result
consist
studi
demonstr
type
ifn
signal
contribut
sarsdriven
patholog
mortal
mice
predict
observ
rsv
infect
peopl
ds
develop
sever
complic
upon
infect
includ
higher
rate
hospit
mortal
hope
result
encourag
special
attent
individu
ds
includ
closer
monitor
hyperinflamm
inclus
clinic
trial
target
immunesuppress
flow
cytometri
whole
blood
lyse
gentli
rbc
lysi
buffer
stain
surfac
marker
fac
buffer
minut
cell
wash
twice
fac
buffer
fix
pfa
minut
fix
wash
cell
analyz
flow
cytometri
use
either
bd
lrsfortessa
cytek
aurora
spectral
cytomet
antibodi
inform
provid
tabl
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
sampl
run
triplic
averag
normal
rrna
primer
sequenc
provid
tabl
cytokin
measur
blood
cytokin
level
measur
use
mesoscal
discoveri
assay
andor
biolegend
legend
plex
assay
per
manufactur
instruct
sampl
analyz
duplic
averag
use
statist
analysi
miss
valu
set
lower
limit
detect
liver
histopatholog
formalinfix
paraffinembed
piec
liver
section
micron
stain
hematoxylin
eosin
h
e
score
liver
patholog
use
procedur
adapt
mice
describ
tabl
primer
qrtpcr
primer
use
qrtpcr
analysi
interferonstimul
gene
rrna
includ
gene
refseq
id
forward
primer
sequenc
revers
primer
sequenc
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
